norcantharidin has been researched along with Carcinoma, Non-Small Cell Lung in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Y; Guo, J; Jin, D; Shao, C; Wang, D; Wu, Y | 1 |
| Bao, Q; Hu, X; Jiang, L; Lv, R; Xiao, D; Xie, J; Zhang, Y | 1 |
| Chen, W; Dai, J; Du, J; Gong, K; Guo, J; Li, X; Wu, Y; Xi, S; Yang, L | 1 |
| Chen, MS; Chi, CW; Hsu, CC; Huang, YC; Kuo, CD; Lee, HC; Lee, LM; Lee, YC; Liao, JF; Lin, AM; Yang, CH; Yin, PH | 1 |
| Au-Yeung, SC; Han, X; Ho, YP; Lin, G; To, KK; Wang, X | 1 |
5 other study(ies) available for norcantharidin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Connective Tissue Growth Factor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Transcription Factors | 2018 |
Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; bcl-2-Associated X Protein; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Methylation; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Membrane Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Wnt Signaling Pathway | 2015 |
Repression of YAP by NCTD disrupts NSCLC progression.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphoproteins; Signal Transduction; Transcription Factors; YAP-Signaling Proteins | 2017 |
Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Division; DNA, Neoplasm; Enzyme Inhibitors; Humans; Leukemia L1210; Liver Neoplasms, Experimental; Lung Neoplasms; Medicine, Chinese Traditional; Mice; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Phosphoprotein Phosphatases; Phytotherapy; Plants, Medicinal; Tumor Cells, Cultured | 2001 |